| BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression AM Roccaro, A Sacco, P Maiso, AK Azab, YT Tai, M Reagan, F Azab, ... The Journal of clinical investigation 123 (4), 1542-1555, 2013 | 836 | 2013 |
| CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy AK Azab, JM Runnels, C Pitsillides, AS Moreau, F Azab, X Leleu, X Jia, ... Blood, The Journal of the American Society of Hematology 113 (18), 4341-4351, 2009 | 484 | 2009 |
| MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma AM Roccaro, A Sacco, B Thompson, X Leleu, AK Azab, F Azab, J Runnels, ... Blood, The Journal of the American Society of Hematology 113 (26), 6669-6680, 2009 | 390 | 2009 |
| Bone marrow microenvironment in multiple myeloma progression S Manier, A Sacco, X Leleu, IM Ghobrial, AM Roccaro BioMed Research International 2012, 2012 | 382 | 2012 |
| Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells AM Roccaro, T Hideshima, N Raje, S Kumar, K Ishitsuka, H Yasui, ... Cancer research 66 (1), 184-191, 2006 | 380 | 2006 |
| Targeting the bone marrow microenvironment in multiple myeloma Y Kawano, M Moschetta, S Manier, S Glavey, GT Görgün, AM Roccaro, ... Immunological reviews 263 (1), 160-172, 2015 | 379 | 2015 |
| Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features AK Azab, J Hu, P Quang, F Azab, C Pitsillides, R Awwad, B Thompson, ... Blood, The Journal of the American Society of Hematology 119 (24), 5782-5794, 2012 | 349 | 2012 |
| The history of the angiogenic switch concept D Ribatti, B Nico, E Crivellato, AM Roccaro, A Vacca Leukemia 21 (1), 44-52, 2007 | 326 | 2007 |
| Engineered nanomedicine for myeloma and bone microenvironment targeting A Swami, MR Reagan, P Basto, Y Mishima, N Kamaly, S Glavey, S Zhang, ... Proceedings of the National Academy of Sciences 111 (28), 10287-10292, 2014 | 281 | 2014 |
| Prognostic role of circulating exosomal miRNAs in multiple myeloma S Manier, CJ Liu, H Avet-Loiseau, J Park, J Shi, F Campigotto, KZ Salem, ... Blood, The Journal of the American Society of Hematology 129 (17), 2429-2436, 2017 | 262 | 2017 |
| Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials B C Potts, M X Albitar, K C Anderson, S Baritaki, C Berkers, B Bonavida, ... Current cancer drug targets 11 (3), 254-284, 2011 | 255 | 2011 |
| Metabolic signature identifies novel targets for drug resistance in multiple myeloma P Maiso, D Huynh, M Moschetta, A Sacco, Y Aljawai, Y Mishima, ... Cancer research 75 (10), 2071-2082, 2015 | 242 | 2015 |
| Erythropoietin as an angiogenic factor D Ribatti, A Vacca, AM Roccaro, E Crivellato, M Presta European journal of clinical investigation 33 (10), 891-896, 2003 | 233 | 2003 |
| Regulation of microRNAs in cancer metastasis JMC Bouyssou, S Manier, D Huynh, S Issa, AM Roccaro, IM Ghobrial Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1845 (2), 255-265, 2014 | 225 | 2014 |
| C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma AM Roccaro, A Sacco, C Jimenez, P Maiso, M Moschetta, Y Mishima, ... Blood, The Journal of the American Society of Hematology 123 (26), 4120-4131, 2014 | 224 | 2014 |
| Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma N Raje, S Kumar, T Hideshima, A Roccaro, K Ishitsuka, H Yasui, ... Blood 106 (3), 1042-1047, 2005 | 214 | 2005 |
| Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and-independent apoptosis K Ishitsuka, T Hideshima, M Hamasaki, N Raje, S Kumar, H Hideshima, ... Blood 106 (5), 1794-1800, 2005 | 212 | 2005 |
| Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs X Leleu, J Soumerai, A Roccaro, E Hatjiharissi, ZR Hunter, R Manning, ... Journal of Clinical Oncology 27 (2), 250-255, 2009 | 194 | 2009 |
| LNA-mediated anti–miR-155 silencing in low-grade B-cell lymphomas Y Zhang, AM Roccaro, C Rombaoa, L Flores, S Obad, SM Fernandes, ... Blood, The Journal of the American Society of Hematology 120 (8), 1678-1686, 2012 | 181 | 2012 |
| The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia X Leleu, X Jia, J Runnels, HT Ngo, AS Moreau, M Farag, JA Spencer, ... Blood, The Journal of the American Society of Hematology 110 (13), 4417-4426, 2007 | 172 | 2007 |
